Search

Your search keyword '"Vaccines -- Product development -- Planning"' showing total 16 results
Start Over Descriptor "Vaccines -- Product development -- Planning" Journal m2 pharma
16 results on '"Vaccines -- Product development -- Planning"'

1. Pfizer, Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15

Subjects
Pfizer Inc. -- Product development -- Planning, Valneva SE -- Product development -- Planning, Euronext Paris S.A. -- Product development -- Planning, Medical research, Medicine, Experimental, Biotechnology industry -- Product development -- Planning, Clinical trials, Vaccines -- Product development -- Planning, Lyme disease, Securities industry -- Product development -- Planning, Pharmaceutical industry -- Product development -- Planning, Securities industry, Company business planning, Chemistry
Abstract

M2 PHARMA-August 10, 2022-Pfizer, Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15 (C)2022 M2 COMMUNICATIONS - US-based pharmaceutical company Pfizer Inc. (NYSE: PFE) and France-based Valneva SE [...]

Published
2022

2. Valneva, Pfizer Report Positive Phase 2 Pediatric Data for Lyme Disease Vaccine Candidate

Subjects
Pfizer Inc. -- Product development -- Planning, Valneva SE -- Product development -- Planning, Euronext Paris S.A. -- Product development -- Planning, Biological products industry -- Product development -- Planning, Pediatrics, Biotechnology industry -- Product development -- Planning, Vaccines -- Product development -- Planning, Lyme disease, Securities industry -- Product development -- Planning, Pharmaceutical industry -- Product development -- Planning, Securities industry, Company business planning, Chemistry
Abstract

M2 PHARMA-April 27, 2022-Valneva, Pfizer Report Positive Phase 2 Pediatric Data for Lyme Disease Vaccine Candidate (C)2022 M2 COMMUNICATIONS - France-based specialty vaccine company Valneva SE (NASDAQ: VALN) (Euronext Paris: [...]

Published
2022

3. Pfizer and BioNTech commence trial of COVID-19 vaccine targeting Omicron variant

Subjects
BioNTech SE -- Product development -- Planning, Pfizer Inc. -- Product development -- Planning, Biotechnology industry -- Product development -- Planning, Clinical trials, Vaccines -- Product development -- Planning, Pharmaceutical industry -- Product development -- Planning, Company business planning, Chemistry
Abstract

M2 PHARMA-January 25, 2022-Pfizer and BioNTech commence trial of COVID-19 vaccine targeting Omicron variant (C)2022 M2 COMMUNICATIONS US pharmaceutical company Pfizer Inc (NYSE:PFE) and its partner, German biotechnology company BioNTech [...]

Published
2022

4. Novavax submits NDA with MHLW in Japan for approval of COVID-19 vaccine

Subjects
Novavax Inc. -- Product development -- Planning, Takeda Pharmaceutical Company Ltd. -- Product development -- Planning, Biotechnology industry -- Product development -- Planning, Vaccines -- Product development -- Planning, Pharmaceutical industry -- Product development -- Planning, Company business planning, Chemistry
Abstract

M2 PHARMA-December 16, 2021-Novavax submits NDA with MHLW in Japan for approval of COVID-19 vaccine (C)2021 M2 COMMUNICATIONS Biotechnology company Novavax Inc (Nasdaq:NVAX) on Wednesday filed a New Drug Application [...]

Published
2021

5. Moderna Touts Positive Top Line Data from Phase 2/3 Study of COVID-19 Vaccine in Children 6 to 11 Years of Age

Subjects
Moderna Inc. -- Product development -- Planning, Biological products industry -- Product development -- Planning, Medical research, Medicine, Experimental, Biotechnology industry -- Product development -- Planning, RNA, Vaccines -- Product development -- Planning, Company business planning, Chemistry
Abstract

M2 PHARMA-October 25, 2021-Moderna Touts Positive Top Line Data from Phase 2/3 Study of COVID-19 Vaccine in Children 6 to 11 Years of Age (C)2021 M2 COMMUNICATIONS - US-based biotechnology [...]

Published
2021

6. Beijing Wantai plans large Phase III trial of nasal spray COVID-19 vaccine candidate

Subjects
Biological products industry -- Product development -- Planning, Respiratory agents, Clinical trials, Vaccines -- Product development -- Planning, Company business planning, Chemistry
Abstract

M2 PHARMA-September 23, 2021-Beijing Wantai plans large Phase III trial of nasal spray COVID-19 vaccine candidate (C)2021 M2 COMMUNICATIONS Beijing Wantai Biological Pharmacy Enterprise (SHA:603392), a Chinese vaccine developer and [...]

Published
2021

7. India approves further clinical trials for first domestic mRNA COVID-19 vaccine

Subjects
Messenger RNA, Clinical trials, Vaccines -- Product development -- Planning, Company business planning, Chemistry
Abstract

M2 PHARMA-August 24, 2021-India approves further clinical trials for first domestic mRNA COVID-19 vaccine (C)2021 M2 COMMUNICATIONS India has approved further clinical trials for its first domestic mRNA-based COVID-19 vaccine, [...]

Published
2021

8. Akston Biosciences Touts Positive Phase I Data for Second-Generation COVID-19 Vaccine Candidate

Subjects
Biological products industry -- Product development -- Planning, Clinical trials, Vaccines -- Product development -- Planning, Company business planning, Chemistry
Abstract

M2 PHARMA-July 9, 2021-Akston Biosciences Touts Positive Phase I Data for Second-Generation COVID-19 Vaccine Candidate (C)2021 M2 COMMUNICATIONS - US-based biologic therapeutics developer Akston Biosciences Corp has released positive results [...]

Published
2021

9. Mexico plans to commence late-stage clinical trial for Walvax's mRNA COVID-19 vaccine

Subjects
Biological products industry -- Product development -- Planning, Messenger RNA, Clinical trials, Vaccines -- Product development -- Planning, Company business planning, Chemistry
Abstract

M2 PHARMA-May 12, 2021-Mexico plans to commence late-stage clinical trial for Walvax's mRNA COVID-19 vaccine (C)2021 M2 COMMUNICATIONS The foreign minister of Mexico, Marcelo Ebrard, stated on Tuesday that Mexico [...]

Published
2021

10. Clover partners with Dynavax for planned Global Phase 2/3 efficacy trial of adjuvanted COVID-19 vaccine candidate

Subjects
Dynavax Technologies Corp. -- Alliances and partnerships -- Product development -- Planning, Biological products industry -- Product development -- Alliances and partnerships -- Planning, Clinical trials, Vaccines -- Product development -- Planning, Pharmaceutical industry -- Alliances and partnerships -- Product development -- Planning, Cooperative agreement for product development, Company business planning, Chemistry
Abstract

M2 PHARMA-February 1, 2021-Clover partners with Dynavax for planned Global Phase 2/3 efficacy trial of adjuvanted COVID-19 vaccine candidate (C)2021 M2 COMMUNICATIONS Biotechnology company Clover Biopharmaceuticals Monday announced its plans [...]

Published
2021

12. China to begin clinical trials of AstraZeneca's COVID-19 vaccine

Subjects
AstraZeneca PLC -- Product development -- Planning, Clinical trials, Vaccines -- Product development -- Planning, Pharmaceutical industry -- Product development -- Planning, COVID-19, Company business planning, Chemistry
Abstract

M2 PHARMA-November 6, 2020-China to begin clinical trials of AstraZeneca's COVID-19 vaccine (C)2020 M2 COMMUNICATIONS A senior executive of British pharmaceutical company AstraZeneca Plc (LON:AZN) has said that the company [...]

Published
2020

13. Germany's CureVac announces its COVID-19 vaccine triggers immune response in Phase I trial

Subjects
Pfizer Inc. -- Product development -- Planning, Clinical trials, Vaccines -- Product development -- Planning, Pharmaceutical industry -- Product development -- Planning, Immune response, COVID-19, Company business planning, Chemistry
Abstract

M2 PHARMA-November 2, 2020-Germany's CureVac announces its COVID-19 vaccine triggers immune response in Phase I trial (C)2020 M2 COMMUNICATIONS German biopharmaceutical company CureVac (Nasdaq:CVAC) has said its experimental COVID-19 vaccine [...]

Published
2020

14. China's Kangtai commences mid-stage trial of its experimental COVID-19 vaccine candidate

Subjects
Clinical trials, Vaccines -- Product development -- Planning, COVID-19, Company business planning, Chemistry
Abstract

M2 PHARMA-October 29, 2020-China's Kangtai commences mid-stage trial of its experimental COVID-19 vaccine candidate (C)2020 M2 COMMUNICATIONS Chinese Clinical Trial Registry has revealed that Shenzhen Kangtai Biological Products (Kangtai), a [...]

Published
2020

15. Shionogi's CEO says Japanese COVID-19 vaccine ready for December trial

Subjects
Shionogi & Company Ltd. -- Product development -- Planning, Clinical trials, Vaccines -- Product development -- Planning, Business planning, Pharmaceutical industry -- Product development -- Planning, COVID-19, Company business planning, Chemistry
Abstract

M2 PHARMA-October 29, 2020-Shionogi's CEO says Japanese COVID-19 vaccine ready for December trial (C)2020 M2 COMMUNICATIONS Shionogi & Co, a drug-discovery based Japanese pharmaceutical company, is planning clinical trials by [...]

Published
2020

16. Philippines to begin clinical trials of Russia's COVID-19 vaccine in October 2020

Subjects
Philippines News Agency -- Product development -- Planning, Cable News Network -- Product development -- Planning, Clinical trials, Vaccines -- Product development -- Planning, Cable television broadcasting industry -- Product development -- Planning, COVID-19, Company business planning, Chemistry
Abstract

M2 PHARMA-August 13, 2020-Philippines to begin clinical trials of Russia's COVID-19 vaccine in October 2020 (C)2020 M2 COMMUNICATIONS CNN reported on Thursday that the Philippines is planning to begin clinical [...]

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results